Robert Dood

ORCID: 0000-0003-4302-6983
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Endometrial and Cervical Cancer Treatments
  • Ovarian cancer diagnosis and treatment
  • Cancer, Stress, Anesthesia, and Immune Response
  • Metabolomics and Mass Spectrometry Studies
  • Neuropeptides and Animal Physiology
  • Uterine Myomas and Treatments
  • Estrogen and related hormone effects
  • Advanced Proteomics Techniques and Applications
  • Mass Spectrometry Techniques and Applications
  • Endometriosis Research and Treatment
  • Cancer survivorship and care
  • Immune cells in cancer
  • Adipose Tissue and Metabolism
  • Cytokine Signaling Pathways and Interactions
  • Multiple and Secondary Primary Cancers
  • Cancer Cells and Metastasis
  • Cancer, Lipids, and Metabolism
  • Radiomics and Machine Learning in Medical Imaging
  • Economic and Financial Impacts of Cancer
  • Nerve injury and regeneration
  • Cancer-related molecular mechanisms research
  • Ferroptosis and cancer prognosis
  • Cancer Genomics and Diagnostics
  • Maternal and fetal healthcare
  • Histone Deacetylase Inhibitors Research

Huntsman Cancer Institute
2021-2025

University of Utah
2021-2024

The University of Texas MD Anderson Cancer Center
2017-2022

Intermountain Healthcare
2022

Community Link
2022

Gynecologic Oncology Group
2017

University of Pennsylvania
2012-2016

Hospital of the University of Pennsylvania
2014

Philadelphia University
2014

Thrombocytosis is present in more than 30% of patients with solid malignancies and correlates worsened patient survival. Tumor cell interaction various cellular components the tumor microenvironment including platelets crucial for growth metastasis. Although it known that can infiltrate into tissue, secrete pro-angiogenic pro-tumorigenic factors thereby increase growth, precise molecular interactions between metastatic cancer cells are not well understood. Here we demonstrate induce...

10.1038/s41467-017-00411-z article EN cc-by Nature Communications 2017-08-11

Ovarian high-grade serous carcinoma (HGSC) results in the highest mortality among gynecological cancers, developing rapidly and aggressively. Dissimilarly, borderline ovarian tumors (BOT) can progress into low-grade carcinomas have relatively indolent clinical behavior. The underlying biological differences between HGSC BOT call for accurate diagnostic methodologies tailored treatment options, identification of molecular markers aggressiveness could provide valuable biochemical insights...

10.1158/0008-5472.can-16-3044 article EN Cancer Research 2017-04-18

Mounting clinical and preclinical evidence supports a key role for sustained adrenergic signaling in the tumor microenvironment as driver of growth progression. However, mechanisms by which neurotransmitters are delivered to not well understood. Here we present feed-forward loop whereby leads increased tumoral innervation. In response catecholamines, cells produced brain-derived neurotrophic factor (BDNF) an ADRB3/cAMP/Epac/JNK-dependent manner. Elevated BDNF levels innervation through host...

10.1158/0008-5472.can-16-1701 article EN Cancer Research 2018-04-16

The diversity and heterogeneity within high-grade serous ovarian cancer (HGSC), which is the most lethal gynecologic malignancy, not well understood. Here, we perform comprehensive multi-platform omics analyses, including integrated analysis, immune monitoring on primary metastatic sites from highly clinically annotated HGSC samples based a laparoscopic triage algorithm patients who underwent complete gross resection (R0) or received neoadjuvant chemotherapy (NACT) with excellent poor...

10.1016/j.celrep.2020.03.066 article EN cc-by-nc-nd Cell Reports 2020-04-01

// Yasmin A. Lyons 1 , Sunila Pradeep Sherry Y. Wu Monika Haemmerle Jean M. Hansen Michael J. Wagner Alejandro Villar-Prados Archana S. Nagaraja Robert L. Dood Rebecca Previs Wei Hu Yang Zhao 4 Duncan H. Mak, 7 Zhilan Xiao 5 Brenda D. Melendez Gregory Lizee Imelda Mercado-Uribe 6 Keith Baggerly Patrick Hwu Jinsong Liu Willem W. Overwijk Coleman and Anil K. Sood 1,2,3 Departments of Gynecologic Oncology Reproductive Medicine, The University Texas MD Anderson Cancer Center, Houston, TX, USA 2...

10.18632/oncotarget.20410 article EN Oncotarget 2017-08-24

Adrenergic signaling is known to promote tumor growth and metastasis, but the effects on stroma are not well understood. An unbiased bioinformatics approach analyzing samples from patients with biobehavioral profiles identified a prominent stromal signature associated cancer-associated fibroblasts (CAFs) in those high risk profile (high Center for Epidemiologic Studies Depression Scale [CES-D] score low social support). In several models of epithelial ovarian cancer, daily restraint stress...

10.1172/jci.insight.93076 article EN JCI Insight 2017-08-16

Survivorship involves a multidisciplinary approach to surveillance and management of comorbidities secondary cancers, overseen by oncologists, surgeons, primary care physicians. Optimal timing coordination care, however, is unclear often based on arbitrary 5-year cutoffs.To determine high- low-risk periods for all tumor types that could define when survivorship might best be oncologists transition physicians.In this pan-cancer, longitudinal, observational study, excess mortality hazard,...

10.1001/jamaoncol.2018.2761 article EN JAMA Oncology 2018-06-02

To evaluate the association between prophylactic ureteral stent placement at time of hysterectomy for placenta accreta spectrum and genitourinary injury.We conducted a retrospective cohort study patients with who underwent two referral centers from 2001 to 2021. The exposure was placement. primary outcome, injury, composite bladder or vesicovaginal fistula. Secondary outcomes included components outcome. We evaluated differences groups using χ 2 t test. in we reported odds ratios (ORs)...

10.1097/aog.0000000000004957 article EN Obstetrics and Gynecology 2022-10-06

Abstract Angiosarcoma is an aggressive malignancy of endothelial cells that carries a high mortality rate. Cytotoxic chemotherapy can elicit clinical responses, but the duration response limited. Sequencing reveals multiple mutations in angiogenesis pathways angiosarcomas, particularly vascular growth factor (VEGFR) and mitogen-activated protein kinase (MAPK) signaling. We aimed to determine biological relevance these angiosarcoma. Tissue microarray consisting formalin-fixed paraffin...

10.1038/s41598-021-88703-9 article EN cc-by Scientific Reports 2021-04-30

PURPOSE Endometrial cancer (EC) is the most common gynecologic in United States with rising incidence and mortality. Despite optimal treatment, 15%-20% of all patients will recur. To better select for adjuvant therapy, it important to accurately predict at risk recurrence. Our objective was train, validate, test models EC recurrence using lasso regression other machine learning (ML) deep (DL) analytics a large, comprehensive data set. METHODS Data from were downloaded Oncology Research...

10.1200/po-24-00859 article EN JCO Precision Oncology 2025-05-01

Abstract The prognostic and therapeutic value of the tumor microenvironment (TME) in various cancer types is major interest. Characterization TME often relies on a small representative tissue sample. However, adequacy such sample for assessing components not yet known. Here, we used immunohistochemical (IHC) staining 7-color multiplex to evaluate CD8 (cluster differentiation 8), CD68, PD-L1 (programmed death-ligand 1), CD34, FAP (fibroblast activation protein), cytokeratin 220 cores from 26...

10.1038/s41598-019-53872-1 article EN cc-by Scientific Reports 2019-11-26

Although progesterone receptor (PR)-targeted therapies are modestly active in patients with uterine cancer, their underlying molecular mechanisms not well understood. The clinical use of such is limited because the lack biomarkers that predict response to PR agonists (progestins) or antagonists (onapristone). Thus, understanding action will provide an advance developing novel combination for cancer patients. Nuclear translocation has been reported be ligand-dependent -independent. Here, we...

10.1158/1535-7163.mct-17-0006 article EN Molecular Cancer Therapeutics 2017-12-14

Establishing an accurate histologic diagnosis is essential for determining the appropriate course of therapy ovarian cancer. This study sought to investigate and describe nonovarian cancer pathologies discovered during systematic laparoscopic workup presumed advanced cancer.A retrospective cohort patients with (based on elevated CA125 and/or imaging) presenting our center without confirmed pathologic were identified characterized. Patients final pathology described compared those epithelial...

10.1097/igc.0000000000001329 article EN cc-by-nc-nd International Journal of Gynecological Cancer 2018-07-23

6528 Background: Survivorship involves a multidisciplinary approach to surveillance and management of comorbidities secondary cancers, however timing is based on arbitrary 5 year cutoffs. Here, we used novel method analyzing annualized mortality rates systematically define these cut-offs for transitions care. Methods: The SEER database was queried survival data patients aged 18-100 years with any incident diagnosis cancer, grouped by ICD-O-3 tumor type. Excess hazard, calculated as an risk...

10.1200/jco.2018.36.15_suppl.6528 article EN Journal of Clinical Oncology 2018-05-20

5591 Background: Kentucky has the highest incidence and mortality from gynecologic cancer in United States, of endometrial (EC) Appalachian (AP) population is even higher than non-Appalachian (non-AP). The purpose this study to compare demographics, molecular profiles, outcomes between AP non-AP populations. Methods: Using Total Cancer Care prospective cohort study, we evaluated 836 women with EC, 40 (4.8%), 700 (83.7%), 96 unknown residence (11.5%). We used descriptive statistics univariate...

10.1200/jco.2024.42.16_suppl.5591 article EN Journal of Clinical Oncology 2024-06-01

Nearly a decade ago The Cancer Genome Atlas 2013 analysis used sequencing data to cluster endometrial cancers into four distinct molecular subtypes with survival patterns, rather than relying on traditional clinicopathologic criteria. Subsequent studies have validated these

10.1136/ijgc-2022-003709 article EN cc-by-nc-nd International Journal of Gynecological Cancer 2022-06-15
Coming Soon ...